Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. April 2019 08:30 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx’ Ampligen and Pembrolizumab

OCALA, Fla., April 02, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell...
01. April 2019 17:30 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Reports 2018 Year-end Financial Results

OCALA, Fla., April 01, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces financial results for the fiscal year ended December 31, 2018, and provides a business...
13. März 2019 09:06 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs

OCALA, Fla., March 13, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D company focused on unmet medical needs in...
06. März 2019 08:25 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering

OCALA, Fla., March 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company...
28. Februar 2019 10:30 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Announces Dutch Health Inspectorate Approval to Extend the Ampligen Pancreatic Cancer Early Access Program Until March 2020

OCALA, Fla., Feb. 28, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on...
28. Februar 2019 08:30 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019

OCALA, Fla., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company...
27. Februar 2019 08:30 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering

OCALA, Fla., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company...
15. Februar 2019 06:00 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period

OCALA, Fla., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company...
12. Februar 2019 14:17 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record

To be a stockholder of record, investors are advised to own Hemispherx stock by 4:00 PM ET, Tuesday, February 12, 2019 to account for T+2 settlement timing Record date established as Thursday,...
11. Februar 2019 08:30 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Merck’s Keytruda in the Treatment of Recurrent Ovarian Cancer

OCALA, Fla., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on unmet medical needs in immunology and oncology, announced today...

Vorherige Seite

Nächste Seite